Market Newsdesk

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV), the largest gaming platform in North America, reaching over 300 million monthly video game and esports fans worldwide, today announced that it has observed significant growth across a number of key metrics during Black Friday Week, representing the seven-day period from November 24 – 30, 2020, as compared to the corresponding period in 2019 (November 26 – December 2, 2019).

Black Friday is an important event in the digital media industry as there is typically a surge in the demand of digital ad inventory throughout the corresponding week. The Company is pleased to report the following observations for Black Friday Week 2020 vs 2019:

• 36% growth of total advertising revenue, including programmatic advertising revenue growth of 28%
• 12% increase in site views, resulting in nearly 800 million web and video content views in one week
• An additional 2,000 paid subscribers added to the Company’s web properties, representing an approximately 2% increase in monthly recurring subscribers gained in one week

“More and more brands are realizing the untapped value of our gaming and esports platform as an ideal advertising and engagement method to reach the Gen Z and millennial audiences,”
said Adrian Montgomery, CEO of Enthusiast Gaming.
“We are seeing strong growing numbers across our various segments which is a testament to the investments and strategic decisions we undertook during the past year including in ad tech, direct sales, content and distribution. We remain excited and confident about our growth trajectory.”

These results come on the heels of a successful virtual-only EGLX 2020, the fifth annual gaming festival which saw upwards of 12 million viewers across the globe and was supported by key sponsors G Fuel, SpiderTech and TikTok.

About Enthusiast Gaming

Enthusiast Gaming (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV) is building the world’s largest social network of communities for gamers and esports fans that reaches over 300 million gaming enthusiasts on a monthly basis. Already the largest gaming platform in North America and the United Kingdom, the Company’s business is comprised of four main pillars: Esports, Content, Talent and Entertainment. Enthusiast Gaming’s esports division, Luminosity Gaming, is a leading global esports franchise that consists of 7 professional esports teams under ownership and management, including the Vancouver Titans Overwatch team and the Seattle Surge Call of Duty team. Enthusiast’s gaming content division includes 2 of the top 20 gaming media and entertainment video brands with BCC Gaming and Arcade Cloud, reaching more than 50MM unique viewers a month across 9 YouTube pages, 8 Snapchat shows and related Facebook, Instagram and TikTok accounts. Its 100 gaming-related websites including The Sims Resource, Destructoid, and The Escapist collectively generate 1.1 billion page views monthly. Enthusiast’s talent division works with nearly 1,000 YouTube creators generating nearly 3 billion views a month working with leading gamer talent such as Pokimane, Flamingo, Anomaly, and The Sidemen. Enthusiast’s entertainment business includes Canada’s largest gaming expo, EGLX (eglx.com), and the largest mobile gaming event in Europe, Pocket Gamer Connects (pgconnects.com). For more information on the Company visit enthusiastgaming.com. For more information on Luminosity Gaming visit luminosity.gg.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Enthusiast anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the foregoing) be taken, occur, be achieved, or come to pass. Forward-looking statements in this news release include, but are not limited to statements relating to the Enthusiast Gaming’s future growth in periods of increased market advertiser demand.

Forward-looking statements are based on assumptions, including expectations and assumptions concerning: interest and foreign exchange rates; capital efficiencies, cost saving and synergies; growth and growth rates; the success in the esports and media industry; and the Company’s growth plan. While Enthusiast Gaming considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks related risks associated with general economic conditions; adverse industry events; future legislative, tax and regulatory developments. Readers are cautioned that the foregoing list is not exhaustive and other risks set out in Enthusiast Gaming public disclosure recorded filed under the Company’s provide on www.sedar.com, including those contained in the prospectus. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of Enthusiast Gaming which are available on SEDAR at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Enthusiast Gaming disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:
Enthusiast Gaming – Eric Bernofsky
Chief Corporate Officer
[email protected]

Media Relations – ID 
[email protected]

Rogers provides phones and plans to women in crisis; extends previously donated plans by six months with second wave of pandemic

New partnership with
Fédération des maisons d’hébergement pour femmes
,
Regroupement des maisons pour femmes victimes de violence conjugale, and
Alliance des maisons d’hébergement de 2^e étape pour femmes et enfants victimes de violence conjugale

MONTREAL, Dec. 03, 2020 (GLOBE NEWSWIRE) — Deep into the second wave of COVID-19, Rogers Communications today announced it is providing hundreds of free phones, voice and data plans to women’s shelters across Quebec to enable connectivity for women experiencing violence and abuse. A recent report shows that since the start of the pandemic, the severity of violence against women seeking shelters has doubled, causing an urgent need to support women and children who may be facing the reality of being at home with an abusive family member.

“For Quebec women and children escaping abuse, phones and connectivity provide an essential digital lifeline that allows them to access emergency resources safely,” said Edith Cloutier, President of Quebec, Rogers Communications. “When home is no longer a safe place to be, we’re proud to help enable these critical connections for women and children so they can access critical resources from the organizations that support them.”

Expanding on a previous announcement with Quebec women’s shelters like L’Arrêt-Source and Le Chaînon in Montreal last spring, Rogers is providing hundreds of additional phones along with six months of free voice and data plans to women’s shelters across the province. The company is extending all services to the end of June 2021 to bridge connectivity needs as women are experiencing increased isolation during the second COVID-19 wave, with restrictions across Quebec.

Quebec women’s shelters receiving phones and plans include L’Inter Elles in Langelier, Maison Simonne Monet-Chartrand in Chambly, La Maison d’hébergement L’Égide in La Prairie, Le Havre des Femmes in L’Islet, La maison d’Athena in Montréal, Maison secours aux femmes in Montréal, La Clé sur la Porte in St-Hyacinthe,L’Ombre-Elle in Sainte-Agathe-des-Monts, Regroup’elles in Terrebonne, and Havre l’Éclaircie in St-Georges.

“It is crucial for women victims of violence, regardless of the region across Quebec, to be able to communicate easily and quickly with their loved ones, but also to stay in contact with shelter teams in case of need or danger,” said Manon Monastesse, Executive Director, Fédération des maisons d’hébergement pour femmes. “All the more so in this time of the pandemic, during which it is advisable to stay at home and go out as little as possible. Phones are tools that allow women to communicate securely and discreetly with shelters.”

“We know that the pandemic has had a significant impact on women,” said Mathilde Trou, co-responsible for political issues, Regroupement des maisons pour femmes victimes de violence conjugale. “Thanks to these cell phones, the women in our care and staying in our shelters will be able to stay in touch with their loved ones and continue their efforts, without having to worry about the minutes they have left on their phone. This is invaluable help and will be greatly appreciated.”

“A phone is a crucial link for isolated women to maintain contact with their loved ones and our support services during the pandemic,” said Gaëlle Fedida, Political Affairs Coordinator, Alliance des maisons d’hébergement de 2^e étape pour femmes et enfants victimes de violence conjugale. “Having safe phone lines at their disposal, ones that are unknown to their abusive spouse, allows women to concretely move forward towards a new life without violence.”

If you are a woman living in an abusive home, or you know someone who is, you can call your local shelter’s 24/7 crisis line for advice and support. Find your local shelter and its crisis line on sheltersafe.ca/quebec.

In addition to today’s announcement, Rogers previously announced donations of 300 phones and plans to keep Quebec youth connected to mentors. These services have been extended by another six months to bridge connectivity needs during this second wave of COVID-19. This includes phones and plans to organizations like Big Brothers Big Sisters of Greater Montreal to allow “Littles” to stay in regular contact with their “Bigs”, Pflag Montreal for virtual peer mentoring sessions for LGBTQ2S+ youth and their families, and for virtual youth education programs offered by YMCA of Quebec and the Fondation pour les élèves de la Commission scolaire de la région de Sherbrooke.

About Rogers

Rogers is a proud Canadian company dedicated to making more possible for Canadians each and every day. Our founder, Ted Rogers, purchased his first radio station, CHFI, in 1960. We have grown to become a leading technology and media company that strives to provide the very best in wireless, residential, sports, and media to Canadians and Canadian businesses. Our shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). If you want to find out more about us, visit about.rogers.com.

For more information:

Rogers Communications, [email protected], 1-844-226-1338

RXMD Management to Discuss Details Regarding Recently Filed Proxy Statement and Address Shareholder Questions Submitted in Advance

MIAMI, Dec. 03, 2020 (GLOBE NEWSWIRE) — via NewMediaWire – Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, is pleased to announce that the Company has scheduled an investor conference call for 4:30 PM ET on Monday, December 7, 2020.

The Company will address the recently filed proxy statement. In addition, interested parties can submit questions concerning the Company to Stuart Smith at SmallCapVoice.Com, Inc. via email: [email protected] by 5:00 PM ET on Friday, December 4, 2020. In determining the questions that will be addressed, the Company will use its discretion, considering factors such as relevance to the entire shareholder base and appropriateness in light of compliance requirements under applicable securities laws.

To access the call:

Dial-In Number: 1-857-232-0157 Access Code: 422095

For those unable to participate in the live conference call, a replay will be available at https://www.smallcapvoice.com/clients/rxmd/ shortly after the call has concluded. An archived version of the webcast will also be available https://www.progressivecareus.com/news-releases.

Connect and stay in touch with us on social media:

Progressive Care Inc. 
https://www.facebook.com/ProgressiveCareUS/https://twitter.com/ProgressCareUS

PharmCo Rx 
https://www.facebook.com/pharmcorx/https://twitter.com/PharmCoRx

ClearMetrX

https://www.clearmetrx.com/
https://www.facebook.com/clearmetrx/

Progressive Care Inc. (RXMD), through its subsidiaries, is a Florida technology and health services organization that provides prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management. Cautionary Statement Regarding Forward-Looking Statements: Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Public Relations Contact:

Carlos Rangel
[email protected]
www.progressivecareus.com
www.pharmcopharmacy.com

For SmallCapVoice.com, Inc.

Stuart T. Smith 512-267-2430
[email protected]
www.SmallCapVoice.com

DALLAS, Dec. 03, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver cannabinoid compounds, such as CBD, CBG, and CBN, announced today that it has selected Accent Clinical Research Professionals, LLC (”ACCENT”) of Allen, Texas to administer RTSL’ first round of human research of its proprietary CBD and CBG blended MDI. RTSL expects to sign the formal agreement by December 31, 2020.

ACCENT is a clinical research center, specializing in Phase I-IV pharmaceutical and device studies dedicated to providing high quality and reliable research data to sponsors striving to advance today’s medicine while rigorously maintain the safety of patients. The principal investigator of the MDI for the clinical trials is Dr. Neal C. Lawrence, M.D. and Dr. Charles L. Powell, M.D. will be the medical advisor to RTSL.

RTSL’s CEO, Donal R. Schmidt, Jr. states, “Our decision to go with Accent (www.amrprofessionals.com) and the two physicians we chose was quite simple. Accent is known for quality and integrity which has made them a preferred provider for some of the largest pharmaceutical companies. In addition, both physicians are active in research and thoroughly believe in the long-term potential of cannabinoids for use in conjunction with modern treatment modalities. And finally, this team gives RTSL access to a patient pool of over 150,000 trial candidates in the DFW Metroplex with more than ten (10) years of medical data per disease indication.

We intend to run an eight (8) leg study looking at support for anxiety, chronic pain, ADHD, inflammation (this will include COVID-19 pulmonary rehabilitation and recovery), arthritis, insomnia, and depression. We are also discussing testing on “long-haul” Covid-19 recovery patients as well. Each study will have 50 volunteer patients with significant documented disease histories going back more than a decade. The initial protocols will focus on both objective and subjective results which will then be further narrowed for the next round of testing. Eventually, we will narrow our focus to normalize dosage relative to blood plasma levels of each cannabinoid or blend thereof.”

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or CBN. The Company’s Rxoid™ and nhāler product lines are manufactured in compliance with Good Manufacturing Practices (GMP), on FDA-listed equipment. Note that while cannabinoids such as CBD, CBG and CBN are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is generally the most efficient delivery method for an API other than an IV. In addition, MDIs are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. However, MDIs are expensive to formulate and difficult to manufacture in order to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws. Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver exactly the same dose on its first use as well as its 100th use.

RTSL’s MDIs are a safe and technically superior replacement for vape pens, mods and all-in-one products because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bioavailable dose of CBD and/or cannabinoids directly to the systemic blood stream. This allows RTSL to manufacture a scientifically sound and superior alternative to all other cannabinoid vaping systems in a market estimated to be $5 billion in annual sales.

RTSL products will continue to be sold directly to pharmacies, physicians and other healthcare providers who treat GAD, PTSD and other stress and anxiety disorders. nhāler can be purchased online at www.nhaler.com. Rxoid™ currently is unavailable to purchase as its website is being updated. RTSL also produces white label products for select commercial clients.

Now RTSL is entering into the quickly evolving medical grade isolate manufacturing space. RTSL will manufacture CBD, CBG, CBN, and various other minor cannabinoids and terpenes under proprietary processes as it increases its ever growing list of formulas for support of various treatment regiments that physicians and health care providers are beginning to recommend in conjunction with more traditional mainstream medications

We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

Visit our corporate website at www.rtslco.com.

Forward-Looking Statements 

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
[email protected]

Phone: 800-497-6059
Fax: 877-676-8527

EATONTOWN, N.J., Dec. 03, 2020 (GLOBE NEWSWIRE) — Climb Channel Solutions, an international specialty technology distributor, will begin to distribute SUSE’s innovative open source solutions including a best-in-class Linux operating system, a market-leading Kubernetes management platform and a host of pioneering edge capabilities. SUSE is committed to providing dependable, adaptable, and highly flexible open source solutions for the most demanding IT environments.

Modern data centers have become increasingly complex and filled with several different products. Every data center not only needs these products to work, but also needs them all to work well together seamlessly. SUSE’s work with its ecosystem of partners and communities support its delivery of truly open, open source solutions.

“SUSE has entered a new phase of partnerships following the launch of the SUSE One Partner Program in September 2020,” said Joel Petlick, Director of Americas Channel at SUSE. “This streamlined program was created and aligned to fit the needs and expectations of our partner community, all to support partner profitability and joint growth. As a global leader in true open source innovation, SUSE offers customers choices that helps them avoid vendor lock-in and fosters innovation. Climb is an ideal fit for our expansion by introducing SUSE to a partner base that’s emerging-technology focused and providing distribution support that’s agile and committed to our joint success. With Climb, we offer a new element of choice to partners and their customers.”

SUSE works with partners around the globe to bring cutting-edge, SUSE-compatible technology to provide customers options that perfectly fit their needs. These partnerships allow SUSE to power digital transformation for the enterprise by simplifying, modernizing and accelerating traditional cloud and edge solutions.

“SUSE’s flexible business practices, lack of vendor lock -in and exceptional service have given us a great deal of confidence in our partnership,” said Dale Foster, CEO of Climb Channel Solutions. “The addition of SUSE allows us to provide technology that’s both innovative and complementary, along with a full suite of training, consultation, and support solutions to our resellers.”

Those interested in distribution services and solutions should contact Climb by phone at +1.800.847.7078 (US), or +1.888.523.7777 (Canada), or by email at [email protected].

About
Climb Channel Solutions

Climb Channel Solutions, a subsidiary of Wayside Technology Group, Inc. (NASDAQ: WSTG), is an international specialty technology distributor focused on emerging technologies. Climb provides partners with access to Security, Data Management, Virtualization and Cloud, Storage and Hyperconverged Infrastructure, Connectivity, Software and Application Lifecycle, and other technically sophisticated products. The company helps vendors recruit and build multinational solution provider networks, power their networks, and drive incremental sales revenues that complement existing sales channels. Climb services thousands of solution providers, VARs, systems integrators, corporate resellers, and consultants worldwide, helping them power a rich opportunity stream while building profitable businesses.

For additional information visit www.climbcs.com, or call 1.800.847.7078 (US), +1.732.389.0037
(International), +1.888.523.7777 (Canada), or +31.20.210.8005 (Europe).

Follow Climb Channel Solutions on Facebook, LinkedIn and Twitter.

– No unexpected
safety findings
during the course of
the study
–

–
On track to file
an
IND by end of year; Phase 1 clinical trial to commence in early 2021 –

WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert^® technology for wet age-related macular degeneration (wet AMD).

Results from the study showed no EYPT-1901-related adverse ocular or systemic toxicology findings at any dose level studied in the rabbit model. There were no changes in key ocular measurements such as intraocular pressure (IOP) and no changes in liver function enzymes as is often seen with systemic delivery of tyrosine kinase inhibitors. These results provide additional rationale for the advancement of EYP-1901 into clinical development.

“We continue to believe in the potential of EYP-1901 to be a disruptive and beneficial treatment option for patients and physicians for the long-term treatment of wet AMD. These promising safety results reinforce the potential product profile of EYP-1901 and will be included in our Investigational New Drug (IND) submission that is expected to be filed before the end of the year,” said Jay Duker, M.D., Chief Strategic Scientific Officer of EyePoint Pharmaceuticals. “Upon IND allowance by the U.S. Food and Drug Administration (FDA), we plan to rapidly initiate our Phase 1 clinical trial of EYP-1901 and dose our first patient in early 2021.”

About
EYP-1901

EYP-1901 is a potential six-month sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 combines EyePoint’s proprietary bioerodable Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib has established efficacy signals observed in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events reported. Preclinical studies of EYP-1901 administered locally into the eye have shown promising anti-VEGF activity with no serious safety issues observed. EyePoint plans to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by the end of 2020 and expects to initiate a Phase 1 trial in early 2021. EYP-1901 is initially being developed as a treatment for wet AMD, with the potential for future indications in diabetic retinopathy and retinal vein occlusion.

About
EyePoint
Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company’s pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the extent to which our business could be adversely impacted by the effects of the COVID-19 coronavirus pandemic, as well as the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a vital, novel six-month treatment for wet age-related macular degeneration. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the extent to which COVID-19 impacts our business; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME; Alimera’s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera’s ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; our ability to market and sell products; the success of current and future license agreements, including our agreement with Equinox Science; termination or breach of current license agreements, including our agreement with Equinox Science; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Contacts

Investors:
Argot Partners
Sam Martin or Joe Rayne
212-600-1902
[email protected]

Media:
Thomas Gibson
201-476-0322
[email protected]  

Leading sustainability and cleantech communications firm will work directly with SunHydrogen executive leadership to strengthen communications efforts as global demand for renewable hydrogen grows exponentially

SANTA BARBARA, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) — SunHydrogen, Inc. (OTC:HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today announced it has retained New York City-based FischTank PR, a leading sustainability and cleantech PR firm, to drive communications efforts as the Company continues to advance its nanoparticle technology for generation of economical green hydrogen. 

Through its relationship with FischTank PR, SunHydrogen will activate its Twitter and Facebook pages, utilizing both to serve as resources for renewable hydrogen and broader renewable energy news and information, as well as for sharing corporate announcements and materials. The Company also plans to increase shareholder communications via press release and newsletter distribution, highlighting technological milestones, commercialization efforts and other corporate progress.

“As our visibility within the capital markets and energy sector continue to grow, we understand the importance of increased and effective corporate communications,” said Tim Young, CEO of SunHydrogen. “I look forward to working directly with FischTank PR, a firm deeply entrenched in the sustainability and cleantech sector that also understands the importance of transparent, informative communication with security holders.”

FischTank PR was founded in 2013 and is led by CEO Eric Fischgrund and President Matt Bretzius. The firm works with clients commercializing technologies in renewable energy and cleantech sectors spanning energy storage, solar, battery design, green building, agtech and more. The firm’s clients are comprised of private and public companies, the latter of which possesses market caps ranging from small to Fortune 100.

About SunHydrogen, Inc.

SunHydrogen is developing a breakthrough, low-cost technology to make renewable hydrogen using sunlight and any source of water, including seawater and wastewater. Unlike hydrocarbon fuels, such as oil, coal and natural gas, where carbon dioxide and other contaminants are released into the atmosphere when used, hydrogen fuel usage produces pure water as the only byproduct. By optimizing the science of water electrolysis at the nano-level, our low-cost nanoparticles mimic photosynthesis to efficiently use sunlight to separate hydrogen from water, ultimately producing environmentally friendly renewable hydrogen. Using our low-cost method to produce renewable hydrogen, we intend to enable a world of distributed hydrogen production for renewable electricity and hydrogen fuel cell vehicles.  To learn more about SunHydrogen, please visit our website at www.SunHydrogen.com.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein, and while expected, there is no guarantee that we will attain the aforementioned anticipated developmental milestones. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: our ability to successfully negotiate agreements with suppliers and manufacturers of its hydrogen generation panels, our ability to procure project financing, our ability to retain the service of a qualified engineering firm to design and build a pilot plant, our ability to secure an agreement to with a partner with us for the pilot plant, the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

Press Contact:
[email protected] 

Winston-Salem, NC, Dec. 03, 2020 (GLOBE NEWSWIRE) — Inmar Intelligence, a data-driven technology-enabled services company, today released new survey data, which found 61 percent of shoppers switched purchase loyalty to less expensive brands since the start of the pandemic.

Promotions continue to be top of mind for today’s shoppers as they navigate the consumer journey amid the COVID-19 pandemic. This is evident in the survey findings, as 80 percent of shoppers are actively looking for grocery deals, including coupons and promotions, and 92 percent say grocery brands should be doing more to provide cost savings options for consumers. Grocery stores that provide coupons or promotions are more likely to gain repeat business – nearly 60 percent (59 percent) of respondents choose to shop at these stores more frequently due to their promotions. 

In this uncertain climate, consumers are not afraid to try new products if it means saving money. Nearly three quarters (70 percent) of shoppers have actively searched for new types of grocery products or brands during the pandemic and 83 percent plan to purchase these new products again. Shoppers purchased these new products and brands mainly due to cost (67 percent) and because it was on sale or had a coupon associated with it (51 percent), perhaps indicating that retailers and brands must engage with customers to provide personalized and consistent promotions in this increasingly competitive marketplace. 

“COVID-19 continues to impact today’s shoppers who are searching for new ways to save money, especially in terms of groceries,” said David Mounts, Chairman and CEO of Inmar Intelligence. “The survey findings suggest that shoppers expect retailers to provide more promotions and have expressed their willingness to try new brands because of it. So it is crucial for retailers and CPG brands to provide cost savings opportunities, whether this be coupons or other promotional activities to maintain store traffic and protect customer loyalty.” 

Additional key findings include: 

• 44 percent of respondents say the average number of coupons they redeem per week at a grocery store has changed since the beginning of the pandemic.
• Since the start of the pandemic, 39 percent of respondents grocery shop more frequently.
• 43 percent have used a grocery store’s mobile app to order groceries and 41 percent have used it to clip coupons. 

For more information about how Inmar Intelligence can help optimize convenient and personalized promotions for consumers to protect and grow loyalty, please visit https://www.inmar.com/inmarpay.

About Inmar Intelligence

Commerce Accelerated.™ 

Inmar Intelligence is a leading data and tech-enabled services company. $120 billion dollars of commerce runs through our market-driven platforms which are propelling digital transformation through unified data and workflows to help leading Fortune 5000 companies, emerging brands and health systems drive innovation.

Throughout our 40-year history, we have served retailers, manufacturers, pharmacies, health systems, government and employers as their trusted intermediary in helping them redefine success. For more information about Inmar, please follow us on Twitter, LinkedIn or Facebook, or call (866) 440-6917.

Holly Pavlika
Inmar Intelligence
(336) 770-3596
[email protected]

VANCOUVER, British Columbia, Dec. 03, 2020 (GLOBE NEWSWIRE) — Abacus Mining & Exploration Corporation (“Abacus” or the “Company”) (TSXV: AME) wishes to provide an update to its shareholders on the Ajax copper-gold project, located near Kamloops, British Columbia. Abacus holds a 20% ownership interest in the project, which is managed by base metal major KGHM Polska Miedź S.A., who hold the remaining 80%.

Abacus is pleased to report that KGHM has opened a new Kamloops office for the Ajax project within the past two weeks. This follows the appointment in September of a new Ajax Superintendent, who has begun the task of First Nation, community and governmental engagement.

The Ajax Project underwent a joint provincial and federal environmental review starting in 2011, which culminated in the decision by the B.C. Minister of Environment and Climate Change Strategy and the Minister of Energy, Mines and Petroleum Resources to decline to issue an environmental assessment certificate for the Project in December of 2017. Despite this setback, KGHM in consultation with Abacus has continued to work to advance the project, including evaluating various strategies geared toward potentially resubmitting the environmental application.

The Ajax Project contains significant quantities of copper and gold, within a NI 43-101 Proven and Probable Mineral Reserve of 426 Mt at 0.29% Cu, 0.19 g/t Au and 0.39 g/t Ag. Contained metal is in the order of 2.7 Bil lbs Cu, 2.6 Moz Au and 5.3 Moz Ag. (Wardrop Engineering Inc. 2012. Ajax Copper/Gold Project, Kamloops, British Columbia – Feasibility Study Technical Report. Doc. No. 1054610300-REP-R0004-02. January 2012).

Besides Ajax, the Company holds options and leases on the Willow and adjacent Nev-Lorraine copper-molybdenum properties in the Yerington copper camp, southeast of Reno, Nevada. Drilling by the Company in 2018 intersected a key intrusive rock unit on Willow that hosts all known porphyry Cu-Mo deposits at Yerington. This rock unit was not previously known to exist on the Company’s property, and it represents a key new discovery. The target is large and robust, and it remains essentially untested.

The Company also has a lease on the Jersey Valley gold property. The project is within the Battle Mountain trend of north-central Nevada in close proximity to both the Phoenix/Fortitude mine complex (a gold skarn with approximately 14 Moz gold plus significant Ag and Cu past production and a proposed mine life to 2063) and the Cove/McCoy Mine (a Carlin-type gold deposit with 3.4 Moz gold and 110 Moz Ag past production). Data is from the Newmont Mines and Premier Gold Mines websites. The reader is cautioned that the mineralization hosted on nearby properties is not necessarily indicative of mineralization hosted on the Company’s Jersey Valley gold property.

The technical information in this news release has been reviewed and approved by Paul G. Anderson, M.Sc., P.Geo., a Qualified Person within the meaning of National Instrument 43-101.

On Behalf of the Board,
ABACUS MINING & EXPLORATION CORPORATION

Paul G. Anderson
President and COO

About Abacus
Abacus is a mineral exploration and mine development company currently focused on its optioned Willow copper-gold property located near Yerington, Nevada in which it can acquire up to a 75% ownership interest, and the contiguous Nev-Lorraine claims subject to a ten-year lease agreement. The Company also holds a 20% ownership interest, together with KGHM Polska Miedź S.A. (80%), in the proposed copper-gold Ajax Mine located southwest of Kamloops, B.C., which has recently undergone a joint provincial and federal environmental assessment process. On December 14, 2017, a decision was made by the B.C. Minister of Environment and Climate Change Strategy and the Minister of Energy, Mines and Petroleum Resources to decline to issue an environmental assessment certificate for the Project. For the latest reports and information on Abacus’ projects, please refer to the Company’s website at www.amemining.com or call 604-682-0301.

Forward-Looking Information


This release includes certain statements that are deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that Abacus expects to occur, are forward-looking statements. Forward- looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not
guarantees
of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include changes to commodity prices, mine and metallurgical recovery, operating and capital costs, foreign exchange rates, ability to obtain required permits on a timely basis, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward- looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements
in the event that
management’s beliefs, estimates or opinions, or other factors, should change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Tel: 604.682.0301 
email: [email protected]
website: www.amemining.com 

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) — Bonavista Resources Corp. (“Bonavista” or “the Company”) is pleased to recognise that the Prospectors and Developers Association of Canada (“PDAC”) announced that the Company’s Chair, Phillip C. Walford, and its Technical Advisor, Sherry Dunsworth will be awarded the 2021 Bill Dennis Award for the significant mineral discovery made at Marathon Gold Corp’s Valentine Lake property in central Newfoundland.

David Clark, President, comments: “I would like to sincerely congratulate Phill and Sherry for being the 2021 recipients of the Bill Dennis Award, which is our industry’s highest commendation for mineral discovery. Valentine Lake is likely to be Newfoundland’s next operating gold mine. This will be due in no small part to the dedication and hard work of Phill, Sherry, and the exploration team at Marathon Gold. I am proud that Phill and Sherry have chosen Bonavista Resources as their next project. It is strong support for the work done to date and our potential for discovery at Hickey’s Pond.”

About Bonavista Resources

Bonavista is a private exploration company focused on exploring a large landholding in the underexplored Avalonian terrane on the Burin Peninsula, Newfoundland. This underexplored belt has direct analogues at Hope Brook in southwest Newfoundland (First Mining Gold) and Haile in South Carolina (OceanaGold), both multi million-ounce resources hosted in the same geological terrane as the Burin peninsula rocks. Limited historical exploration by previous explorers combined with comprehensive documentation of the overall alteration system by government and academic workers creates a compelling opportunity for the discovery of Newfoundland’s next multi million-ounce gold system. The Company’s Burin Gold Project hosts several historical high-sulphidation gold showings over ~20 km of prospective geology, the best known of which is the Hickey’s Pond showing.

For more information, visit www.bonavistaresources.com or contact:

David Clark, MSc, PGeo, President

[email protected]